COMMUNIQUÉS West-GlobeNewswire

Ex dividend NOK 0.50 today
05/06/2024
The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.50 as from today, 05.06.2024.
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
05/06/2024
New data from the ELATIVE ® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks Data from the itch [...]
Ipsen présente de nouvelles données sur l’efficacité à long terme d’elafibranor et la qualité de vie liée aux démangeaisons chez les patients atteints de cholangite biliaire primitive
05/06/2024
De nouvelles données de l’essai ELATIVE ® de Phase III révèlent que 70 % des patients traités par elafibranor ont atteint le critère d’évaluation composite du ralentissement de la progression de la maladie, mesuré par [...]
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
05/06/2024
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5 Philadelphia) Nantes, [...]
OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale
05/06/2024
OSE Immunotherapeutics et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale Au congrès 2024 [...]
Addex Convenes Annual General Meeting 2024
05/06/2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
05/06/2024
Saint-Herblain (France), June 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“ [...]
Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction
05/06/2024
Saint-Herblain (France), 5 juin 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA) (la « Société »), société spécialisée dans les vaccins, a annoncé aujourd’hui la mise à disposition des documents préparatoires à [...]
Fortrea cède ses activités Endpoint Clinical et Patient Access à Arsenal Capital Partners
05/06/2024
DURHAM, Caroline du Nord, 05 juin 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq : FTRE), un organisme de recherche sous contrat (« ORC ») de premier plan au niveau mondial, a annoncé aujourd’hui avoir finalisé la cession des [...]
Jushi Holdings Inc. Announces Voting Results of Annual Meeting
04/06/2024
BOCA RATON, Fla., June 04, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Corporation”) (CSE: JUSH) (OTCMKTS: JUSHF), a vertically integrated, multi-state cannabis operator, announced the voting results [...]
Annexon Announces Proposed Public Offering of Common Stock
04/06/2024
BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06/2024
BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments
04/06/2024
VIENNA, Austria, June 04, 2024 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has [...]
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
04/06/2024
TORONTO and HAIFA, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing [...]
Vision Sensing Acquisition Corp. Announces Receipt of a Deficiency Notice from Nasdaq for Failure to Timely File its 1st Quarter 2024 Form 10-Q and Announces the Filing of the Form 10-Q
04/06/2024
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced today that on May 30, 2024, the Company [...]
Lifeward to Present at Sidoti Virtual Investor Conference on June 12
04/06/2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing [...]
Cellectis obtient la désignation de médicament orphelin pour son produit CAR T allogénique UCART22 pour les patients atteints de leucémie lymphoblastique aiguë
04/06/2024
NEW YORK, 04 juin 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN [...]
Streamline Health® To Report Fiscal First Quarter 2024 Financial Performance
04/06/2024
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM) , a leading provider of solutions that enable healthcare providers to proactively address [...]
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06/2024
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners [...]

Pages